DE69728975D1 - Rekombinante phagen - Google Patents

Rekombinante phagen

Info

Publication number
DE69728975D1
DE69728975D1 DE69728975T DE69728975T DE69728975D1 DE 69728975 D1 DE69728975 D1 DE 69728975D1 DE 69728975 T DE69728975 T DE 69728975T DE 69728975 T DE69728975 T DE 69728975T DE 69728975 D1 DE69728975 D1 DE 69728975D1
Authority
DE
Germany
Prior art keywords
bacteriophages
bacterial
component
infections
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69728975T
Other languages
English (en)
Other versions
DE69728975T2 (de
Inventor
Sven Mardh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE69728975D1 publication Critical patent/DE69728975D1/de
Application granted granted Critical
Publication of DE69728975T2 publication Critical patent/DE69728975T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/121—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Helicobacter (Campylobacter) (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69728975T 1996-02-06 1997-02-05 Rekombinante phagen Expired - Fee Related DE69728975T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9600434A SE506771C2 (sv) 1996-02-06 1996-02-06 Fusionsprotein, bakteriofag uttryckande proteinet, dessas användning samt hybridoma celler och monoklonaler producerade av cellerna
SE9600434 1996-02-06
PCT/SE1997/000172 WO1997029185A1 (en) 1996-02-06 1997-02-05 Recombinant phages

Publications (2)

Publication Number Publication Date
DE69728975D1 true DE69728975D1 (de) 2004-06-09
DE69728975T2 DE69728975T2 (de) 2005-05-04

Family

ID=20401289

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69728975T Expired - Fee Related DE69728975T2 (de) 1996-02-06 1997-02-05 Rekombinante phagen

Country Status (16)

Country Link
EP (1) EP0889955B1 (de)
JP (1) JP4015195B2 (de)
KR (1) KR100459638B1 (de)
CN (1) CN1125174C (de)
AT (1) ATE266091T1 (de)
AU (1) AU712767B2 (de)
CA (1) CA2244792A1 (de)
DE (1) DE69728975T2 (de)
ES (1) ES2221033T3 (de)
HU (1) HUP9901242A3 (de)
IL (2) IL125645A0 (de)
NO (1) NO323359B1 (de)
NZ (1) NZ331580A (de)
RU (1) RU2215032C2 (de)
SE (1) SE506771C2 (de)
WO (1) WO1997029185A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006717A2 (en) 1998-07-27 2000-02-10 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein
GB9908195D0 (en) 1999-04-09 1999-06-02 Microbiological Res Authority Treatment of intracellular infection
EP1187914B1 (de) 1999-06-14 2005-05-25 Genentech, Inc. Strukturiertes peptidgerüst zur ausstellung von drehung-bibliotheken auf phage
DE60113851T2 (de) * 2000-07-25 2006-07-20 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bakteriophage mit breitem wirtsspektrum
US6914123B2 (en) 2001-04-17 2005-07-05 Genentech, Inc. Hairpin peptides with a novel structural motif and methods relating thereto
KR20040036176A (ko) * 2002-10-23 2004-04-30 (주)엘피스바이오텍 단백질의 특이적 결합을 매개로 한 박테리오파아지의선택적 숙주감염을 이용한 단백질간의 상호작용을분석하는 방법
CN102296051B (zh) * 2011-03-07 2014-09-17 江苏省农业科学院 一种宽宿主谱鸡白痢沙门氏菌噬菌体及其应用
RU2503716C1 (ru) * 2012-09-27 2014-01-10 Федеральное бюджетное учреждение науки Государственный научный центр прикладной микробиологии и биотехнологии (ФБУН ГНЦ ПМБ) ВИДОСПЕЦИФИЧЕСКИЙ ВИРУЛЕНТНЫЙ ШТАММ БАКТЕРИОФАГА, ОБЛАДАЮЩИЙ ЛИТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ Staphylococcus aureus, ВКЛЮЧАЯ МУЛЬТИРЕЗИСТЕНТНЫЕ ШТАММЫ
GB201308745D0 (en) * 2013-05-15 2013-06-26 Imp Innovations Bacteriophage
CN106198523A (zh) * 2016-07-06 2016-12-07 哈尔滨贝贝凯尔科技发展有限公司 微量元素检测试纸及其制备方法
US20200271657A1 (en) 2017-10-04 2020-08-27 Opko Pharmaceuticals, Llc Articles and methods directed to personalized therapy of cancer
CN112739416B (zh) * 2018-12-27 2024-09-06 国立大学法人东海国立大学机构 宿主细菌特异性纳米粒子
CN109679981A (zh) * 2019-02-21 2019-04-26 武汉大学 一种甲酰基肽定向进化噬菌体及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
SE9304060D0 (sv) * 1993-12-06 1993-12-06 Bioinvent Int Ab Sätt att selektera specifika bakteriofager

Also Published As

Publication number Publication date
AU712767B2 (en) 1999-11-18
WO1997029185A1 (en) 1997-08-14
NO983456L (no) 1998-10-06
KR19990082041A (ko) 1999-11-15
EP0889955B1 (de) 2004-05-06
SE506771C2 (sv) 1998-02-09
CA2244792A1 (en) 1997-08-14
JP4015195B2 (ja) 2007-11-28
NO323359B1 (no) 2007-04-10
CN1125174C (zh) 2003-10-22
IL125645A0 (en) 1999-04-11
EP0889955A1 (de) 1999-01-13
AU1681797A (en) 1997-08-28
DE69728975T2 (de) 2005-05-04
NO983456D0 (no) 1998-07-27
NZ331580A (en) 1999-09-29
ATE266091T1 (de) 2004-05-15
KR100459638B1 (ko) 2005-02-24
HUP9901242A2 (hu) 1999-07-28
RU2215032C2 (ru) 2003-10-27
JP2000505648A (ja) 2000-05-16
SE9600434L (sv) 1997-08-07
SE9600434D0 (sv) 1996-02-06
ES2221033T3 (es) 2004-12-16
HUP9901242A3 (en) 2000-03-28
CN1210558A (zh) 1999-03-10
IL125645A (en) 2006-08-20

Similar Documents

Publication Publication Date Title
ATE266091T1 (de) Rekombinante phagen
IL141639A (en) Multicomponent vaccines
DK0587780T3 (da) Smitstof, som forårsager Mystery Swine Disease, vaccinepræparater og diagnostiske sæt
DE60113851D1 (de) Bakteriophage mit breitem wirtspektrum
NO20006191L (no) Vaksine
ES2178000T3 (es) Composiciones y metodos para tratar infecciones usando analogos de indolicidina.
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
DK1476541T3 (da) Cytokin (zcytor17-ligand)
TR200102497T2 (tr) Yeni streptococcus antijenleri
ATE213507T1 (de) Methode zur bindung von material an das beta- amyloid-peptid
TR200002437T2 (tr) B grubu streptococcus antijenleri.
DE60233532D1 (de) An proteinphosphatase 2a bindende synthetische ode anwendungen
AU2197392A (en) Hepatitis C virus from C-100-3 and env/core regions
BR0012919A (pt) Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv
FR21C1005I2 (fr) Antigenes de streptococcus pyogenes et fragments d'adn correspondants
SG144692A1 (en) Antigenic proteins of shrimp white spot syndrome virus and uses thereof
DE69535855D1 (de) Calciumbindende rekombinante antikörper gegen protein c
ATE477274T1 (de) Gegen clostridium difficile gerichtete antikörper
WO2005023992A3 (en) Compositions and methods for inhibiting white spot syndrome virus (wssv) infection
DE69737323D1 (de) Adhesin aus heliobacter pylori, welches an blutgruppenantigene bindet
FR2692282B1 (fr) Clonage du gene codant pour la proteine gp28.5 de t. gondii; fragments peptidiques issus de ladite proteine et leurs applications.
ATE543906T1 (de) Antigen von streptococcus aus der b-gruppe
EA200100395A1 (ru) Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием
DK1075523T3 (da) Strukturelle proteiner hos fiskepankreassygdomsvirus og anvendelser deraf
DE69938130D1 (de) Neue peptide

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee